Alliance Pharma PLC Notification of Preliminary Results & Analyst Call (9447H)
March 30 2020 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 9447H
Alliance Pharma PLC
30 March 2020
30 March 2020
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Preliminary Results,
Analyst Conference Call and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare
group, will announce its preliminary results for the year ended 31
December 2019 on Tuesday 7 April 2020.
A conference call for analysts will be held at 10.00am on the
morning of 7 April 2020; analysts who require dial-in details,
please contact Buchanan at alliancepharma@buchanan.uk.com .
A recorded webcast of the analyst conference call, including
investor presentation slides, will be made available during the
afternoon of 7 April 2020 at this link:
https://webcasting.buchanan.uk.com/broadcast/5e416265397af40afa52d7c4
The recorded webcast will also be made available at the investor
section of Alliance's website,
https://www.alliancepharmaceuticals.com/investors/ .
For more information, please contact Buchanan on 020 7466 5000
or email alliancepharma@buchanan.uk.com .
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Huw Jeremy
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating revenues in more than 100
countries.
We currently own or license the rights to around 90 consumer
healthcare products and pharmaceuticals, which are managed on a
portfolio basis according to their growth potential. Promotional
investment is focused on a small number of brands with significant
international or multi-territory reach. The remainder of the
portfolio comprises products which are sold in a limited number of
local markets and require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOREAXDXADFEEFA
(END) Dow Jones Newswires
March 30, 2020 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024